These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35254917)

  • 21. Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
    Lin G; Yi L; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(7):e0134174. PubMed ID: 26218263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring preferences for
    Wee JW; Png WY; Wong XY; Kwan YH; Lin YY; Tan DS; Wee HL
    Future Cardiol; 2020 Nov; 16(6):663-674. PubMed ID: 32524837
    [No Abstract]   [Full Text] [Related]  

  • 23. Is there a benefit for
    van den Broek WW; Ten Berg JM
    Pharmacogenomics; 2021 Aug; 22(12):727-730. PubMed ID: 34251288
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of the
    Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
    Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
    Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
    JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation.
    Baturina O; Andreev D; Fedina L; Mirzaev K; Ivashchenko D; Ryzhikova K; Grishina E; Bochkov P; Shevchenko R; Sychev D
    Pharmacology; 2022; 107(3-4):216-226. PubMed ID: 35073541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
    Ayesh BM; Al-Astal IR; Yassin MM
    Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clopidogrel and Genotyping.
    Ford NF
    J Invasive Cardiol; 2015 Aug; 27(8):E173-4. PubMed ID: 26232022
    [No Abstract]   [Full Text] [Related]  

  • 32. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
    Cavallari LH; Lee CR
    Future Cardiol; 2019 Jul; 15(4):251-254. PubMed ID: 31385522
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision Antiplatelet Therapy for CYP2C19 Genotype Variants for Achieving Better Clinical Outcomes.
    Cha JJ; Lim DS
    JACC Cardiovasc Interv; 2021 Jul; 14(13):1500-1501. PubMed ID: 34238560
    [No Abstract]   [Full Text] [Related]  

  • 36. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
    Dong P; Yang X; Bian S
    Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reply: Precision Antiplatelet Therapy for CYP2C19 Genotype Variants for Achieving Better Clinical Outcomes.
    Pereira NL; Rihal CS; Farkouh ME
    JACC Cardiovasc Interv; 2021 Jul; 14(13):1501. PubMed ID: 34238561
    [No Abstract]   [Full Text] [Related]  

  • 39. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
    He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.